Publication date: Apr 11, 2019
This post was originally published on this site Rituximab-treated multiple sclerosis (MS) patients who take vitamin D supplements have less inflammatory activity, a study reports. Vitamin D is suggested to have a link with the immune system, and low circulating levels of vitamin D have been associated with an increase of inflammatory activity in MS patients. At UmecE5 University Hospital in Sweden, MS patients treated simultaneously with rituximab and vitamin D supplements were found to have less inflammatory activity, suggesting a possible relationship between rituximab-treated MS patients’ vitamin D levels and inflammatory activity. The post Higher Vitamin D Levels in Rituximab-treated MS Patients Linked to Lower Inflammatory Activity, Study Suggests appeared first on Multiple Sclerosis News Today. The post Higher Vitamin D Levels in Rituximab-treated MS Patients Linked to Lower Inflammatory Activity, Study Suggests appeared first on BioNewsFeeds.
- Efficacy and safety of alemtuzumab in a real-life cohort of patients with multiple sclerosis.
- Is Gadolinium-based Contrast Material Needed for MRI Follow-up of Multiple Sclerosis?
- Cortical Lesions on 7-T MRI in Multiple Sclerosis: A Window into Pathogenetic Mechanisms?
- Analysis of TWEAK Protein Levels May Help Identify Active Inflammation in MS Patients, Study Suggests
- Vitamin D as an immune modulator in multiple sclerosis.
- Mayzent ‘Will Change Lives’ of MS Patients Transitioning to SPMS, Novartis Says